Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.
PlainTrials
RecruitingNot a traditional drug phaseinterventionalRules rewrite

Not a traditional drug phase: Portal Message with Reminder Text Messages for Lung Cancer

To measure the real-world effectiveness and implementation strategies for mPATH-Lung, investigators propose a pragmatic, randomly assigned controlled trial across an academic Learning Health System. The trial will contrast several approaches to participant outreach and will specifically target engaging fully powered cohorts of racial/ethnic minorities and rural residents.

Official registry: https://clinicaltrials.gov/study/NCT07322367 · Wake Forest University Health Sciences · enrollment listed as 27,000

What this phase means

This study does not use the classic phase 1–4 drug ladder. It may be a device, a behavior program, a surgery timing study, or an early feasibility test.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

If you join, the listed intervention(s) are Portal Message with Reminder Text Messages, Text Message with Reminder Text Messages, or Portal message only. The registry lists allocation as randomized. To measure the real-world effectiveness and implementation strategies for mPATH-Lung, investigators propose a pragmatic, randomly assigned controlled trial across an academic Learning Health System.

They plan to enroll about 27,000 people at Winston-Salem. Taking part typically means study visits and measurements plus check-ins.

Official title (unrewritten)

A Pragmatic Randomized-Controlled Learning Health System Trial

Interventions: Portal Message with Reminder Text Messages, Text Message with Reminder Text Messages, Portal message only, Usual Care

Primary outcome (registry wording): Number of Participants to Complete Lung Screening CT - Primary Effectiveness

Who it is for (from inclusion criteria)

  • Ages 50 Years to 77 Years
  • Eligible patients will:
  • Meet the Medicare criteria for lung cancer screening, as updated in February 2022:
  • Smoked at least 20 pack years
  • Current smoker or quit smoking within the past 15 years
  • Have a patient portal account or cellphone number listed in the electronic health record
  • Have a North Carolina address listed in the electronic health record

Public study contact (from the registry)

Study Coordinator

704-355-2000

Aliza.randazzo@advocatehealth.org

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

1 listed

Related recruiting trials in this snapshot

RecruitingNot a traditional drug phaseBethesda, Maryland
Evaluation for NCI Surgery Branch Clinical Research Protocols

Background: The National Cancer Institute Surgery Branch (NCI-SB) has developed experimental therapies that involve taking white blood cells from patients' tumor or from their blood, growing them in the laboratory in large numbers, and then giving the cells back to the patient. Objective: This study will allow patients to under screening and evaluation for participation in NC-SB Protocols.

NCT00001823 · Official ClinicalTrials.gov record · National Cancer Institute (NCI)

FAQ about this NCT record

Is NCT07322367 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT07322367?

Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT07322367?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary